Medeon Biodesign, Inc. (TPEX:6499)

Market Cap	8.03B +115.9%
Revenue (ttm)	419.43M +43.2%
Net Income	-668.06M
EPS	-7.24
Shares Out	96.94M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	437,647
Average Volume	541,871
Open	81.20
Previous Close	81.10
Day's Range	80.80 - 83.00
52-Week Range	51.30 - 154.50
Beta	0.58
RSI	43.90
Earnings Date	May 8, 2026

About Medeon Biodesign

Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to pr...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2012
• Employees: 39
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6499

Financial Performance

In 2025, Medeon Biodesign's revenue was 419.43 million, an increase of 43.24% compared to the previous year's 292.81 million. Losses were -668.06 million, -17.06% less than in 2024.